Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TC-5214 Clear all
Completed Phase 2 Interventional

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

NCT03404570
View directory record Official record
Conditions
Palmar Hyperhidrosis
Interventions
Dexmecamylamine HCl, Placebo
Drug · Other
Lead sponsor
Atacama Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

NCT01868516
View directory record Official record
Conditions
Overactive Bladder
Interventions
dexmecamylamine, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
125
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

NCT01403922
View directory record Official record
Conditions
Chronic Hypertension
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Overland Park, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01152554
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 4, 2026, 2:17 AM EDT
Terminated Phase 1Phase 2 Interventional

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977
View directory record Official record
Conditions
Refractory Hypertension
Interventions
Placebo, TC-5214
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768
View directory record Official record
Conditions
Healthy
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

NCT01458899
View directory record Official record
Conditions
Healthy Subjects
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 4, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 4, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 4, 2026, 2:17 AM EDT